Approvals in 2022: overall survival, dose optimization, new approvals and beyond
Nature Reviews Clinical Oncology, Published online: 23 February 2023; doi:10.1038/s41571-023-00741-6In 2022, the FDA approved numerous new drug and biologic agents, including targeted small molecules, immunotherapeutics, a gene therapy and a radiopharmaceutical. Several drug development challenges were also addressed, and key focus areas for the FDA Oncology Center of Excellence included ongoing monitoring of the Accelerated Approval programme and drug dose optimization. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - February 23, 2023 Category: Cancer & Oncology Authors: Deepti Telaraja Nicole Gormley Richard Pazdur Source Type: research
Sublobar resection is non-inferior to lobectomy in very early stage NSCLC
Nature Reviews Clinical Oncology, Published online: 21 February 2023; doi:10.1038/s41571-023-00743-4Sublobar resection is non-inferior to lobectomy in very early stage NSCLC (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - February 21, 2023 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Rare molecular subtypes of lung cancer
Nature Reviews Clinical Oncology, Published online: 20 February 2023; doi:10.1038/s41571-023-00733-6Lung cancers harbouring ‘rare’ alterations (defined as those with a prevalence of (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - February 20, 2023 Category: Cancer & Oncology Authors: Guilherme Harada Soo-Ryum Yang Emiliano Cocco Alexander Drilon Source Type: research
Cancer-associated cachexia — understanding the tumour macroenvironment and microenvironment to improve management
Nature Reviews Clinical Oncology, Published online: 20 February 2023; doi:10.1038/s41571-023-00734-5Cachexia is a multi-organ syndrome characterized by substantial weight loss that affects a majority of patients with cancer and contributes to cancer-related mortality. The authors of this Review discuss the contribution of both the tumour macroenvironment and microenvironment to the inflammatory and metabolic processes involved in cancer-associated cachexia and provide an overview of the therapeutic strategies developed to manage this syndrome. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - February 20, 2023 Category: Cancer & Oncology Authors: Josep M. Argil és Francisco J. L ópez-Soriano Britta Stemmler Silvia Busquets Source Type: research
Multiomics STEP up in correlative analysis of response to CAR T cells
Nature Reviews Clinical Oncology, Published online: 15 February 2023; doi:10.1038/s41571-023-00742-5Plasma cell-free DNA analysis has emerged as a powerful liquid biopsy assay to assess circulating tumour DNA in response to cancer treatments. A new study shows that cell-free DNA can also inform on expansion kinetics and tumour-infiltration patterns in patients receiving chimeric antigen receptor T cells and, together with circulating tumour DNA, provides vivid prognostic insights into intratumoural dynamics. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - February 15, 2023 Category: Cancer & Oncology Authors: Mark B. Leick Marcela V. Maus Source Type: research
Protein degraders enter the clinic — a new approach to cancer therapy
Nature Reviews Clinical Oncology, Published online: 13 February 2023; doi:10.1038/s41571-023-00736-3Protein degraders constitute a new class of agents that eliminate, rather than just inhibit, their target proteins. These novel agents have recently entered testing in oncology trials, with initial data providing clinical proof of concept for the mechanism of action as well as the antitumour activity of heterobifunctional protein degraders. In this Review, the authors outline the progress in the development of such protein degraders for the treatment of cancer and consider prospects and potential challenges for these agents....
Source: Nature Reviews Clinical Oncology - February 13, 2023 Category: Cancer & Oncology Authors: Deborah Chirnomas Keith R. Hornberger Craig M. Crews Source Type: research
Docetaxel-based CRT improves survival in cisplatin-ineligible patients
Nature Reviews Clinical Oncology, Published online: 10 February 2023; doi:10.1038/s41571-023-00740-7Docetaxel-based CRT improves survival in cisplatin-ineligible patients (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - February 10, 2023 Category: Cancer & Oncology Authors: David Killock Source Type: research
Early data indicate safety of allogeneic CAR T cells
Nature Reviews Clinical Oncology, Published online: 07 February 2023; doi:10.1038/s41571-023-00739-0Early data indicate safety of allogeneic CAR T cells (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - February 7, 2023 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
GPRC5D as a novel immunotherapeutic target in multiple myeloma
Nature Reviews Clinical Oncology, Published online: 01 February 2023; doi:10.1038/s41571-023-00735-4The development of modern immune-based therapies for multiple myeloma has expanded rapidly over the past several years, and GPRC5D has been identified as a viable immunotherapeutic target. Herein, we discuss data and provide future perspectives on GPRC5D-directed CAR T cells and bispecific antibodies for patients with relapsed and/or refractory multiple myeloma. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - February 1, 2023 Category: Cancer & Oncology Authors: Karthik Nath Bruno A. Costa Sham Mailankody Source Type: research
Adjuvant S-1 extends OS in biliary tract cancers
Nature Reviews Clinical Oncology, Published online: 01 February 2023; doi:10.1038/s41571-023-00738-1Adjuvant S-1 extends OS in biliary tract cancers (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - February 1, 2023 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Advancing CAR T cell therapy through the use of multidimensional omics data
Nature Reviews Clinical Oncology, Published online: 31 January 2023; doi:10.1038/s41571-023-00729-2Data obtained using omics technologies can offer important insights into various aspects of chimeric antigen receptor (CAR) T cell therapy. In this Review, the authors provide an overview of the multidimensional profiling technologies that have been applied in investigations of CAR T cell therapy. They then discuss the ways in which multi-omics data obtained through such analyses can be used to elucidate CAR targets, factors associated with response or resistance to therapy, and mechanisms underlying the associated toxicities...
Source: Nature Reviews Clinical Oncology - January 31, 2023 Category: Cancer & Oncology Authors: Jingwen Yang Yamei Chen Ying Jing Michael R. Green Leng Han Source Type: research
Early MRD predicts disease recurrence and benefit from adjuvant chemotherapy in CRC
Nature Reviews Clinical Oncology, Published online: 30 January 2023; doi:10.1038/s41571-023-00737-2Early MRD predicts disease recurrence and benefit from adjuvant chemotherapy in CRC (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - January 30, 2023 Category: Cancer & Oncology Authors: David Killock Source Type: research
Exploring a new pathway for biomarker-based approval of immunotherapies
Nature Reviews Clinical Oncology, Published online: 27 January 2023; doi:10.1038/s41571-023-00731-8The revolution of immunotherapies in oncology has not been matched by the development of companion diagnostic biomarkers able to identify the ideal target populations. Aside from the established pathways for regulatory approval relying on predefined biomarkers, a novel approach based on post hoc biomarker analysis could potentially be instrumental in enhancing the cost-effectiveness of cancer immunotherapy. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - January 27, 2023 Category: Cancer & Oncology Authors: Josep M. Llovet Source Type: research
Neoadjuvant pembrolizumab shows promise in MSI-H/dMMR solid tumours
Nature Reviews Clinical Oncology, Published online: 17 January 2023; doi:10.1038/s41571-023-00732-7Neoadjuvant pembrolizumab shows promise in MSI-H/dMMR solid tumours (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - January 17, 2023 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Novel assessment of epigenetic imprinting biomarkers for the diagnosis of thyroid nodules
Nature Reviews Clinical Oncology, Published online: 16 January 2023; doi:10.1038/s41571-022-00720-3Caring for individuals with thyroid nodules requires accurate estimation of their risk of thyroid cancer; however, available diagnostic tools offer only imprecise estimates. Novel biomarkers might help to clarify thyroid cancer risk and facilitate more-accurate diagnostic decision-making, although limitations in this area continue to exist. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - January 16, 2023 Category: Cancer & Oncology Authors: Naykky Singh Ospina Juan P. Brito Source Type: research
